drugset / Trial / NCT00518193

Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix

NCT00518193 ↗

Phase 2 Terminated 44 enrolled ARCAGY/ GINECO GROUP
NaSingle-groupOpen-labelTreatment

Summary

The efficacy of chimiotherapy in cervix epithelial cancer is low even with the association cisplatine - topotecan . News thérapeutics are needed in the goal of increase the survival and quality of life in patients with cervix cancer. Cetuximab has shown the potentialisation on the efficacy of cisplatine and irinotecan. Cisplatine and topotecan have shown an efficacy in cervix cancer. Cetuximab is well tolerate. Many clinical trials shown the faisability of the association of cetuximab and cisplatine in cancer. Many clinical trials have shown the faisability of association of cetuximab and irinotecan in colorectals metastatiques cancers .

Timeline

Start
2007-04
Primary completion
2007-07
Completion
2008-09

Outcome

Outcome not reported

Stopped: “high rate of medullar aplasia with infectious troubles.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 —

Indications